Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jun 13, 2014
NATICK, Mass., June 13, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced initial Phase 1 data from patients with...
-
Jun 9, 2014
NATICK, Mass., June 9, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Jun 2, 2014
NATICK, Mass., June 2, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced multiple presentations of clinical data from an...
-
May 31, 2014
NATICK, Mass., May 31, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced multiple presentations of clinical data from an...
-
May 30, 2014
NATICK, Mass., May 30, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
May 22, 2014
NATICK, Mass., May 22, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the upcoming presentation of clinical and...
-
May 20, 2014
NATICK, Mass., May 20, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
May 19, 2014
NATICK, Mass., May 19, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
May 7, 2014
NATICK, Mass., May 7, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
May 5, 2014
NATICK, Mass., May 5, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Apr 29, 2014
NATICK, Mass., April 29, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Apr 24, 2014
NATICK, Mass., April 24, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Apr 22, 2014
NATICK, Mass., April 22, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Apr 21, 2014
NATICK, Mass., April 21, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Apr 15, 2014
NATICK, Mass., April 15, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Apr 10, 2014
NATICK, Mass., April 10, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Apr 8, 2014
NATICK, Mass., April 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Mar 5, 2014
NATICK, Mass., March 5, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Feb 27, 2014
NATICK, Mass., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Feb 26, 2014
NATICK, Mass., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Feb 6, 2014
NATICK, Mass., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Jan 22, 2014- Data Demonstrate Preliminary Evidence of Anti-Tumor Activity of Oral Selinexor in Colorectal Cancer Patients -
NATICK, Mass., Jan. 22, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Jan 14, 2014
NATICK, Mass., Jan. 14, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Jan 8, 2014
NATICK, Mass., Jan. 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Dec 20, 2013
NATICK, Mass., Dec. 20, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Dec 11, 2013
NATICK, Mass., Dec. 11, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Dec 8, 2013
NATICK, Mass., Dec. 8, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Dec 7, 2013
NATICK, Mass., Dec. 7, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Dec 5, 2013
NATICK, Mass., Dec. 5, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Dec 2, 2013
NATICK, Mass., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Nov 8, 2013
NATICK, Mass., Nov. 8, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class...
-
Nov 5, 2013
Karyopharm Therapeutics Announces Pricing of Initial Public OfferingNATICK, Mass., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on...
-
Oct 22, 2013
Karyopharm Therapeutics Announces Oral Presentations at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) XPO1 Antagonists in preclinical...
-
Oct 7, 2013
Karyopharm Therapeutics Files Registration Statement for Proposed Initial Public OfferingNatick, Mass. – October 7, 2013 – Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company...
-
Oct 3, 2013
Karyopharm Therapeutics Announces Appointment of Garen Bohlin to Board of DirectorsNatick, Mass. – October 3, 2013 – Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company...
-
Aug 7, 2013
Karyopharm Therapeutics Announces Preclinical Data for Selinexor (KPT-330) in Acute Myeloblastic Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Models at FASEB Science Research...
-
Jul 31, 2013Karyopharm Therapeutics Secures $19 Million in Series B Financing Extension
Natick, Mass. – July 31, 2013 – Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing first-in-class nuclear transport modulators for the treatment of...
-
Jun 2, 2013
Karyopharm Therapeutics Presents Clinical Data for Selinexor (KPT-330), a First-in-Class Selective Inhibitor of Nuclear Export (SINE), in Solid Tumors at the 2013 ASCO Annual MeetingNatick, Mass....
-
May 28, 2013
Karyopharm Therapeutics to Present New Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 EHA CongressNatick, Mass. – May 28, 2013 – Karyopharm Therapeutics Inc., a leader...
-
May 20, 2013
Karyopharm Therapeutics Raises $48.2 Million in Series B FinancingNatick, Mass. – May 20, 2013 – Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, today...
-
May 15, 2013
Karyopharm Therapeutics to Present Clinical Data on Selective Inhibitors of Nuclear Export (SINE), KPT-330, at 2013 ASCO Annual MeetingNatick, Mass. – May 15, 2013 – Karyopharm Therapeutics...
-
May 9, 2013
Karyopharm Therapeutics to Present Data on Selective Inhibitors of Nuclear Export (SINE) to treat Influenza and HIV at International Congress on Antiviral Research (ICAR)Natick, Mass. May 9, 2013...
-
Mar 26, 2013
Karyopharm Therapeutics Announces 15 Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models at the American Association of Cancer Research (AACR)...
-
Feb 5, 2013
Karyopharm Therapeutics Announces Ken Weg & Barry Greene Join Board of Directors; Dr. Sharon Shacham Named President of Research & DevelopmentNatick, Mass. February 5th 2013 Karyopharm...
-
Jan 17, 2013
Karyopharm Therapeutics Initiates Treatment of Patients with Acute Myeloid Leukemia (AML) in Phase 1 Trial with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE)Natick, Mass....
-
Dec 4, 2012
Karyopharm Therapeutics Initiates a Phase IIb Efficacy Study with its Novel, Oral Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Dogs with Non-Hodgkin Lymphomas (NHL)Natick, Mass....
-
Nov 13, 2012
Karyopharm Therapeutics Announces Eight Presentations on Selective Inhibitors of Nuclear Export (SINE) for Hematologic Malignancies at the American Society of Hematology (ASH) MeetingNatick, Mass....
-
Nov 12, 2012Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
Natick, Mass. November 12, 2012 Karyopharm Therapeutics Inc., leading the new field of nuclear transport modulators, announces an oral presentation on the use of its SINE CRM1 antagonists for the...
-
Oct 31, 2012
Karyopharm Therapeutics Announces Multiple Publications on Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in CancerNatick, Mass. October 31st, 2012 Karyopharm Therapeutics Inc.,...
-
Oct 31, 2012
Karyopharm Therapeutics Announces Multiple Publications on Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in CancerNatick, Mass. October 31st, 2012 Karyopharm Therapeutics Inc.,...